Results 21 to 30 of about 57,759 (194)

GBM tumors are heterogeneous in their fatty acid metabolism and modulating fatty acid metabolism sensitizes cancer cells derived from recurring GBM tumors to temozolomide

Frontiers in Oncology, 2022
Glioblastoma is a highly lethal grade of astrocytoma with very low median survival. Despite extensive efforts, there is still a lack of alternatives that might improve these prospects. We uncovered that the chemotherapeutic agent temozolomide impinges on
Sweta Parik, Sweta Parik, Sweta Parik, Sweta Parik, Juan Fernández-García, Juan Fernández-García, Francesca Lodi, Francesca Lodi, Karen De Vlaminck, Karen De Vlaminck, Marleen Derweduwe, Steven De Vleeschouwer, Raf Sciot, Wietse Geens, Linqian Weng, Francesca Maria Bosisio, Francesca Maria Bosisio, Gabriele Bergers, Gabriele Bergers, Johnny Duerinck, Frederick De Smet, Diether Lambrechts, Diether Lambrechts, Jo A. Van Ginderachter, Jo A. Van Ginderachter, Sarah-Maria Fendt, Sarah-Maria Fendt   +26 more
doaj   +1 more source

Hypofractionated Radiation Therapy with Temozolomide for Patients with Glioblastoma Multiforme Recursive Partitioning Analyzes Class V and VI

Southern Clinics of Istanbul Eurasia, 2019
INTRODUCTION[|]This study was performed to determine whether adjuvant temozolomide and 45 Gy/15 fr hypofractionated radiotherapy (RT) can be used to shorten the treatment duration in glioblastoma multiforme (GBM) patients with poor prognostic factors ...
Fuzuli Tuğrul, Gokhan Yaprak, Atilla Arslankaya, Naciye Işık   +3 more
doaj   +1 more source

The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma

Fluids and Barriers of the CNS, 2018
Background The blood–brain barrier (BBB) severely limits the entry of systemically administered drugs including chemotherapy to the brain. In rodents, regadenoson activation of adenosine A2A receptors causes transient BBB disruption and increased drug ...
Sadhana Jackson, Jon Weingart, Edjah K. Nduom, Thura T. Harfi, Richard T. George, Dorothea McAreavey, Xiaobu Ye, Nicole M. Anders, Cody Peer, William D. Figg, Mark Gilbert, Michelle A. Rudek, Stuart A. Grossman   +12 more
doaj   +1 more source

Lymphoproliferative disorder during temozolomide therapy; a representative case of a formidable complication and management challenges

BMC Neurology, 2023
Background Lymphoproliferative disorder represents a heterogeneous clinicopathological spectrum characterized by uncontrolled proliferation of lymphocytes. Immunodeficiency is a major trigger of its development.
Daisuke Sato, Hirokazu Takami, Shunsaku Takayanagi, Kazuki Taoka, Mariko Tanaka, Reiko Matsuura, Shota Tanaka, Nobuhito Saito   +7 more
doaj   +1 more source

Inhibiting stearoyl‐CoA desaturase suppresses bone metastatic prostate cancer by modulating cellular stress, mTOR signaling, and DNA damage response

FEBS Letters, EarlyView.
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson, Mackenzie K Herroon, Shane Mecca, Laimar C Garmo, Jacob Lindquist, Shrila Rajendran, Steve M. Patrick, Izabela Podgorski   +7 more
wiley   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

The challenges of managing glioblastoma multiforme in developing countries: a trade-off between cost and quality of care

Hematology/Oncology and Stem Cell Therapy, 2011
BACKGROUND AND OBJECTIVES: The management of glioblastoma multiforme (GBM) in developing countries is hindered by the paucity of clear protocols due in part to growing economic constraints and the lack of availability of expensive chemotherapeutic agents.
Ahmed Salem, Sameh A. Hashem, Abdulla Al-Rashdan, Najeeb Ezam, Ala’a Nour, Amer Alsharbaji, Maher Sughayer, Issa Mohamad, Maher Elyan, Ala’a Addas, Maysa Al-Hussaini, Abdelatif Almousa   +11 more
doaj   +1 more source

Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma. [PDF]

PLoS ONE, 2018
Glioblastoma multiforme (GBM) is a highly heterogeneous and aggressive brain tumor with a dismal prognosis. Development of resistance towards cytostatic drugs like the GBM standard drug temozolomide is a severe problem in GBM treatment.
Doreen William, Madlin Walther, Björn Schneider, Michael Linnebacher, Carl Friedrich Classen   +4 more
doaj   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source